Stock·NASDAQ·Technology
Akamai Technologies Inc. (AKAM)
- Market cap
- $13.27B
- P/E
- 36.21
- Dividend yield
- 0.00%
- Street target
- $161.50median of 24 analysts
- 52-week range
- $70.82 $165.45
The short version
Where AKAM stands today, in four lines, and what CleaRank Financial AI makes of it.
AKAM at a glance
Akamai Technologies Inc. (AKAM): Sell, 25/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($109.36 and $112.26).
- Earnings AKAM beat estimates in 7 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $20.0M and bought $3.8M over the last 18 months.
- Valuation P/E of 36.2 against 35.1 for the Technology sector: broadly in line with peers (+3%).
Figures as of October 15, 2026.
CleaRank Financial AI
Akamai Technologies Inc. (AKAM) is trading at $92.32, significantly below its 50-day and 200-day moving averages ($109.36 and $112.26), indicating a bearish trend.
The stock's 14-day RSI is 33.87, signaling bearish momentum, and its MACD is negative, further reinforcing a cautious technical outlook. Despite these technical indicators, the median Wall Street price target of $161.50 suggests a potential upside of 74.9%, driven by 24 analysts covering the stock. However, substantial insider selling, with total sales of $20.01 million against $3.83 million in purchases, presents a significant risk. The company's revenue growth has been modest at 5.4%, and forward estimates show a slight contraction in the current year.
Only on CleaRank
Figures we compute ourselves from AKAM's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $92.32 is 15.6% below the 50-day simple moving average of $109.36.Price above its 200-day average ›
The price is 17.8% below the 200-day simple moving average of $112.26.50-day average above the 200-day ›
The 50-day average ($109.36) is 2.6% below the 200-day average ($112.26), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 23% of its 52-week range, between $70.82 and $165.45.
AKAM share price
Pick a period: each tab shows how far AKAM has moved over it, to the last close.
Today's trading
Where AKAM sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/4P/E below the sector median ›
The trailing P/E of 36.21 is 3.2% above the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 3.32 is 56.3% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $411.0M on revenue of $4.3B, a net margin of 9.5%.Beat estimates in most recent reports ›
AKAM beat the EPS estimate in 7 of its last 8 reports.
Key statistics
The headline figures for AKAM.
As of October 15, 2026, AKAM trades at $92.32, with a market value of $13.27B and a P/E ratio of 36.21.
What the numbers say
CleaRank Financial AI's reading of AKAM's valuation, growth and risks.
Akamai Technologies Inc. (AKAM) exhibits a Price-to-Sales ratio of 3.32, which is below the sector median of 7.6, suggesting it may be relatively cheaper on a sales basis compared to its peers.
However, its P/E ratio of 36.21 is slightly above the sector median of 35.1, indicating a premium valuation relative to earnings. The company's Return on Equity (ROE) is 8.92%, which is below the sector average of 13.4%. Profit margins are also mixed, with a net profit margin of 9.51% and an operating margin of 7.63%, both of which are lower than the sector's revenue growth of 24.2%. The company's debt-to-equity ratio stands at 1.97, which is in line with the sector average. Despite the valuation metrics, the company's revenue growth of 5.4% is considerably lower than the sector average, raising concerns about its ability to justify its current valuation and its future growth prospects.
AKAM against the Technology sector
How AKAM compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (3% difference), suggesting fair market pricing relative to industry standards.
Return vs XLK: Since May 5, 2025, AKAM has gained 11.1% against a gain of 74.3% for XLK.
Performance against XLK
AKAM and the Technology sector fund over the same days.
Revenue and earnings
How much AKAM sells, and how much of it becomes profit.
Revenue growth: Revenue grew 5.4% in FY2025 to $4.2B, from $4.0B a year earlier.
Profit margin: The net margin was 10.7% in FY2025, down from 12.7% the year before.
Profitable: AKAM earned $452M in FY2025.
Earnings reality check
Did AKAM beat what analysts expected, and how did the stock react?
Earnings record: AKAM beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | $1.58 | $1.59 | +0.63% | -6.76% | +5.69% |
| May 7, 2026after close | $1.60 | $1.61 | +0.63% | +26.58% | +33.40% |
| Feb 19, 2026after close | $1.75 | $1.84 | +5.14% | -14.07% | -8.84% |
| Nov 6, 2025after close | $1.64 | $1.86 | +13.41% | +14.71% | +21.47% |
| Aug 7, 2025after close | $1.53 | $1.73 | +13.07% | -5.66% | -0.66% |
| May 8, 2025after close | $1.57 | $1.70 | +8.28% | -10.76% | -10.45% |
| Feb 20, 2025after close | $1.52 | $1.66 | +9.21% | -21.73% | -20.57% |
| Nov 7, 2024after close | $1.59 | $1.59 | +0.00% | -14.40% | -15.37% |
As of October 15, 2026, AKAM has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on August 6, 2026, came in 0.63% above the estimate and the stock moved -6.76% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 33.9, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 33.9 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of AKAM
The score, the reasoning behind it, and what could move the price next.
Akamai Technologies Inc. (AKAM) is currently trading below its 50-day SMA of $109.36 and its 200-day SMA of $112.26, indicating a bearish trend.
The 14-day RSI is 33.9, which is in the 'BEARISH' territory, suggesting weakening momentum and potential for further downside. The MACD is also negative at -3.76, reinforcing the bearish sentiment. The stock's current price of $92.32 is below its 20-day EMA of $104.10, highlighting immediate selling pressure. The current price is approaching levels not seen in over a year, suggesting potential psychological support. Volume on the latest day was 8.4 million shares, significantly above the average of 5.1 million, indicating increased trading activity which, in conjunction with bearish technicals, could signal capitulation or further downside. The stock's stochastic indicator is at 21.29, also indicating oversold conditions, but this does not negate the bearish momentum indicated by the RSI and MACD. The CCI is significantly negative at -196.41, further confirming the strong bearish trend. Given these indicators, the technical picture for AKAM is predominantly bearish, with immediate resistance likely at the 50-day SMA and the 20-day EMA.
Median Wall Street Price Target of $161.50 ›
The median price target from 24 analysts suggests a potential upside of 74.9% from the current price, indicating an optimistic view from the analyst community.
Source: Wall Street SummaryMixed Earnings Performance and Guidance ›
While Akamai has a history of beating EPS estimates, the stock price reaction has been negative following the latest report, and forward estimates show a decline.
Source: Earnings Data
Bearish Technical Momentum Confirmed ›
The 14-day RSI at 33.87 and prices trading below its 50-day and 200-day moving averages ($109.36 and $112.26) suggest a continuation of the current downtrend.
Source: Technical Analysis Data
- A sustained break above the 50-day SMA ($109.36) would be a key technical signal to watch for a potential trend reversal.
Technical indicators
Momentum and trend for AKAM, from its daily closes.
As of October 15, 2026, with AKAM at $92.32, its 14-day RSI is 33.9 (showing bearish momentum without being oversold), its 50-day simple moving average is $109.36 and its 200-day is $112.26.
Calculated by CleaRank on daily closes as of October 15, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What AKAM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 15, 2026, AKAM's 1-year correlation of daily returns is +0.37 with S&P 500 (SPY), +0.38 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and +0.08 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
15 of 24 analysts rate it a buy or strong buy, 8 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $161.50 is 74.9% above the price.More buy ratings than three months ago ›
15 of 24 rate it a buy now, against 14 of 25 three months ago.
AKAM Wall Street View
12-month price targets
The price, $92.32, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2026 | DA Davidson | Maintains | Buy |
| Sep 29, 2026 | DA Davidson | Maintains | Buy |
| Sep 28, 2026 | DA Davidson | Maintains | Buy |
| Sep 25, 2026 | UBS | Maintains | Neutral |
| Sep 25, 2026 | Piper Sandler | Reiterates | Overweight |
| Sep 25, 2026 | DA Davidson | Maintains | Buy |
As of October 15, 2026, 24 Wall Street analysts cover AKAM: 15 rate it a buy or strong buy, 8 a hold and 1 a sell or strong sell. Their 12-month price targets range from $93.00 to $225.00, with a median of $161.50, 74.9% above the price of $92.32.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
AKAM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
AKAM moves about 3.9% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much AKAM tends to move, against the market and on its own.
The long record
AKAM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 3.89% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 46.8%, from February 2024 to April 2025, regained by May 2026.Most 1-year holds ended higher ›
61% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $16,693, against $42,405 in the S&P 500 (SPY).
AKAM Drawdowns & Recovery
As of October 15, 2026, AKAM's worst peak-to-trough fall over the last 10 years with dividends reinvested was -46.8% (February 2024 to April 2025); it regained that peak by May 2026, 13 months after the low, and 61% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into AKAM in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: AKAM trailed the S&P 500 over this period: $16,693 against $42,405.
A $10,000 investment in AKAM in October 2016 would be worth about $16,693 today with dividends reinvested, compared with about $42,405 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to AKAM, and which have not.
Strongest month, January: an average of +5.20%, up in 9 of 10 years.
Weakest month, February: an average of -7.40%, up in 3 of 10 years.
This month, October: has averaged -1.44%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, AKAM's strongest calendar month has been January (average +5.20%, up in 9 of 10 years) and its weakest February (average -7.40%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in AKAM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AKAM today could grow to about $17,620 by 2036 in the base case, with a 90th-percentile outcome near $74,521 and a 10th-percentile outcome around $4,166. Projections are statistical simulations, not guarantees.
AKAM Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $116 for AKAM by 2030 in the base case, from $92.32 today (1.3x over 4 years). The 10th-percentile path ends near $46.52. These are outcomes of a Monte Carlo simulation run on AKAM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $61.92 | $97.70 | $154 | |
| 2028 | $54.25 | $103 | $197 | |
| 2029 | $49.67 | $109 | $241 | |
| 2030 | $46.52 | $116 | $288 | |
| 2031 | $44.20 | $123 | $340 |
Method: a lognormal simulation of AKAM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
AKAM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $3.8M on the open market and sold $20.0M.
As of October 15, 2026, AKAM insiders reported 35 open-market sales worth $20.0M and 2 open-market purchases worth $3.8M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Mani Sundaram
Officer
|
Sell | 7.0K | $882.1K |
| Sep 25, 2026 | Kim Salem-Jackson
Officer
|
Sell | 2.0K | $257.7K |
| Sep 15, 2026 | Paul C Joseph
Officer
|
Sell | 3.1K | $327.5K |
| Sep 11, 2026 | Laura Howell
Officer
|
Grant | 323 | - |
| Jul 15, 2026 | Paul C Joseph
Officer
|
Sell | 3.1K | $393.0K |
| Jun 18, 2026 | Robert Blumofe
Chief Technology Officer
|
Sell | 243 | $31.4K |
| Jun 12, 2026 | Laura Howell
Officer
|
Grant | 322 | - |
| Jun 10, 2026 | Kim Salem-Jackson
Officer
|
Sell | 2.3K | $311.8K |
| May 20, 2026 | Daniel R Hesse
Director
|
Grant | 2.3K | - |
| May 14, 2026 | Janaki Akella
Director
|
Grant | 3.0K | - |
| May 14, 2026 | Bas Burger
Director
|
Grant | 3.0K | - |
| May 14, 2026 | Jonathan Frank Miller
Director
|
Grant | 3.5K | - |
| Mar 16, 2026 | Paul C Joseph
Officer
|
Sell | 5.0K | $531.3K |
| Mar 16, 2026 | Aaron Ahola
General Counsel
|
Sell | 4.5K | $478.2K |
| Mar 12, 2026 | Adam M Karon
Officer
|
Sell | 17.0K | $1.8M |
| Mar 12, 2026 | Laura Howell
Officer
|
Grant | 322 | - |
| Mar 11, 2026 | Anthony P Williams
Officer
|
Sell | 15.0K | $1.6M |
| Mar 10, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Sell | 13.7K | $1.4M |
| Mar 9, 2026 | Mani Sundaram
Officer
|
Sell | 1.7K | $169.8K |
| Mar 6, 2026 | Aaron Ahola
General Counsel
|
Grant | 5.6K | - |
| Mar 6, 2026 | Robert Blumofe
Chief Technology Officer
|
Grant | 5.1K | - |
| Mar 6, 2026 | Laura Howell
Officer
|
Grant | 2.0K | - |
| Mar 6, 2026 | Paul C Joseph
Officer
|
Grant | 6.7K | - |
| Mar 6, 2026 | Adam M Karon
Officer
|
Grant | 10.9K | - |
| Mar 6, 2026 | F Thomson Leighton
Chief Executive Officer
|
Grant | 23.4K | - |
| Mar 6, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Grant | 9.0K | - |
| Mar 6, 2026 | Kim Salem-Jackson
Officer
|
Grant | 5.8K | - |
| Mar 6, 2026 | Mani Sundaram
Officer
|
Grant | 6.7K | - |
| Mar 6, 2026 | Anthony P Williams
Officer
|
Grant | 6.5K | - |
| Mar 5, 2026 | Mani Sundaram
Officer
|
Sell | 3.2K | $324.7K |
| Mar 4, 2026 | Jonathan Frank Miller
Director
|
Sell | 11.0K | $1.1M |
| Mar 4, 2026 | Mani Sundaram
Officer
|
Sell | 8.6K | $875.0K |
| Mar 4, 2026 | Madhu Ranganathan
Director
|
Sell | 3.1K | $319.4K |
| Mar 4, 2026 | Aaron Ahola
General Counsel
|
Grant | 5.0K | - |
| Mar 4, 2026 | Robert Blumofe
Chief Technology Officer
|
Grant | 3.5K | - |
| Mar 4, 2026 | Laura Howell
Officer
|
Grant | 1.1K | - |
| Mar 4, 2026 | Paul C Joseph
Officer
|
Grant | 5.7K | - |
| Mar 4, 2026 | Adam M Karon
Officer
|
Grant | 8.4K | - |
| Mar 4, 2026 | F Thomson Leighton
Chief Executive Officer
|
Grant | 20.3K | - |
| Mar 4, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Grant | 6.6K | - |
| Mar 4, 2026 | Kim Salem-Jackson
Officer
|
Grant | 4.0K | - |
| Mar 4, 2026 | Mani Sundaram
Officer
|
Grant | 6.2K | - |
| Mar 4, 2026 | Anthony P Williams
Officer
|
Grant | 5.5K | - |
| Mar 3, 2026 | Aaron Ahola
General Counsel
|
Grant | 7.9K | - |
| Mar 3, 2026 | Robert Blumofe
Chief Technology Officer
|
Grant | 5.3K | - |
| Mar 3, 2026 | Laura Howell
Officer
|
Grant | 1.7K | - |
| Mar 3, 2026 | Paul C Joseph
Officer
|
Grant | 8.4K | - |
| Mar 3, 2026 | Adam M Karon
Officer
|
Grant | 13.1K | - |
| Mar 3, 2026 | F Thomson Leighton
Chief Executive Officer
|
Grant | 28.3K | - |
| Mar 3, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Grant | 10.3K | - |
| Mar 3, 2026 | Kim Salem-Jackson
Officer
|
Grant | 5.9K | - |
| Mar 3, 2026 | Mani Sundaram
Officer
|
Grant | 9.1K | - |
| Mar 3, 2026 | Anthony P Williams
Officer
|
Grant | 8.5K | - |
| Mar 2, 2026 | Adam M Karon
Officer
|
Sell | 4.7K | $458.2K |
| Feb 25, 2026 | Laura Howell
Officer
|
Sell | 11.3K | $1.1M |
| Feb 24, 2026 | Aaron Ahola
General Counsel
|
Sell | 7.5K | $740.0K |
| Feb 20, 2026 | Aaron Ahola
General Counsel
|
Grant | 6.1K | - |
| Feb 20, 2026 | Robert Blumofe
Chief Technology Officer
|
Grant | 6.6K | - |
| Feb 20, 2026 | Laura Howell
Officer
|
Grant | 3.5K | - |
| Feb 20, 2026 | Paul C Joseph
Officer
|
Grant | 8.4K | - |
| Feb 20, 2026 | Adam M Karon
Chief Operating Officer
|
Grant | 9.2K | - |
| Feb 20, 2026 | F Thomson Leighton
Chief Executive Officer
|
Grant | 24.1K | - |
| Feb 20, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Grant | 7.3K | - |
| Feb 20, 2026 | Kim Salem-Jackson
Officer
|
Grant | 5.9K | - |
| Feb 20, 2026 | Mani Sundaram
Officer
|
Grant | 6.4K | - |
| Feb 20, 2026 | Anthony P Williams
Officer
|
Grant | 6.0K | - |
| Feb 19, 2026 | Aaron Ahola
General Counsel
|
Grant | 8.7K | - |
| Feb 19, 2026 | Robert Blumofe
Chief Technology Officer
|
Grant | 7.9K | - |
| Feb 19, 2026 | Paul C Joseph
Officer
|
Grant | 10.3K | - |
| Feb 19, 2026 | Adam M Karon
Officer
|
Grant | 16.8K | - |
| Feb 19, 2026 | F Thomson Leighton
Chief Executive Officer
|
Grant | 36.1K | - |
| Feb 19, 2026 | Edward J Mcgowan
Chief Financial Officer
|
Grant | 13.9K | - |
| Feb 19, 2026 | Kim Salem-Jackson
Officer
|
Grant | 8.9K | - |
| Feb 19, 2026 | Mani Sundaram
Officer
|
Grant | 10.3K | - |
| Feb 19, 2026 | Anthony P Williams
Officer
|
Grant | 10.0K | - |
| Feb 13, 2026 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.5K | $378.0K |
| Jan 22, 2026 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.5K | $339.5K |
| Jan 15, 2026 | Paul C Joseph
Officer
|
Sell | 5.0K | $450.9K |
| Jan 2, 2026 | Adam M Karon
Officer
|
Sell | 3.3K | $289.8K |
| Dec 15, 2025 | Edward J Mcgowan
Chief Financial Officer
|
Sell | 6.6K | $577.5K |
| Dec 12, 2025 | Laura Howell
Officer
|
Grant | 322 | - |
| Dec 5, 2025 | Laura Howell
Officer
|
Grant | 33 | - |
| Dec 1, 2025 | Mani Sundaram
Officer
|
Sell | 10.4K | $931.6K |
| Nov 17, 2025 | Paul C Joseph
Officer
|
Sell | 5.0K | $438.5K |
| Nov 14, 2025 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.0K | $263.1K |
| Nov 7, 2025 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.5K | $301.0K |
| Sep 15, 2025 | Paul C Joseph
Officer
|
Sell | 5.0K | $383.3K |
| Sep 12, 2025 | Laura Howell
Officer
|
Grant | 322 | - |
| Sep 5, 2025 | Laura Howell
Officer
|
Grant | 33 | - |
| Aug 22, 2025 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.0K | $231.0K |
| Aug 20, 2025 | Aaron Ahola
General Counsel
|
Sell | 4.0K | $303.0K |
| Aug 11, 2025 | Daniel R Hesse
Director
|
Buy | 3.0K | $216.9K |
| Aug 11, 2025 | F Thomson Leighton
Chief Executive Officer
|
Buy | 50.0K | $3.6M |
| Jul 15, 2025 | Paul C Joseph
Officer
|
Sell | 5.0K | $388.7K |
| Jun 12, 2025 | Robert Blumofe
Chief Technology Officer
|
Sell | 3.3K | $253.7K |
| Jun 12, 2025 | Laura Howell
Officer
|
Grant | 322 | - |
| Jun 6, 2025 | Laura Howell
Officer
|
Grant | 33 | - |
| May 27, 2025 | Kim Salem-Jackson
Officer
|
Sell | 13.2K | $1.0M |
| May 19, 2025 | Bernardus Johannes Maria Verwaayen
Director
|
Grant | 2.1K | - |
| May 12, 2025 | Sharon J.d. Bowen
Director
|
Grant | 2.8K | - |
| May 9, 2025 | Monte E. Ford
Director
|
Grant | 3.3K | - |
| May 9, 2025 | Jonathan Frank Miller
Director
|
Grant | 3.0K | - |
| May 9, 2025 | Bernardus Johannes Maria Verwaayen
Director
|
Grant | 3.4K | - |
| May 8, 2025 | Adam M Karon
Officer
|
Sell | 3.9K | $333.9K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 15, 2026.